177 related articles for article (PubMed ID: 35920658)
21. Neutralizing Antibodies Induced by Gene-Based Hydrodynamic Injection Have a Therapeutic Effect in Lethal Influenza Infection.
Yamazaki T; Nagashima M; Ninomiya D; Ainai A; Fujimoto A; Ichimonji I; Takagi H; Morita N; Murotani K; Hasegawa H; Chiba J; Akashi-Takamura S
Front Immunol; 2018; 9():47. PubMed ID: 29416543
[TBL] [Abstract][Full Text] [Related]
22. Passive immunization with neutralizing antibodies interrupts the mouse mammary tumor virus life cycle.
Mpandi M; Otten LA; Lavanchy C; Acha-Orbea H; Finke D
J Virol; 2003 Sep; 77(17):9369-77. PubMed ID: 12915552
[TBL] [Abstract][Full Text] [Related]
23. Protective efficacy of passive immunization with monoclonal antibodies in animal models of H5N1 highly pathogenic avian influenza virus infection.
Itoh Y; Yoshida R; Shichinohe S; Higuchi M; Ishigaki H; Nakayama M; Pham VL; Ishida H; Kitano M; Arikata M; Kitagawa N; Mitsuishi Y; Ogasawara K; Tsuchiya H; Hiono T; Okamatsu M; Sakoda Y; Kida H; Ito M; Quynh Mai L; Kawaoka Y; Miyamoto H; Ishijima M; Igarashi M; Suzuki Y; Takada A
PLoS Pathog; 2014 Jun; 10(6):e1004192. PubMed ID: 24945244
[TBL] [Abstract][Full Text] [Related]
24. Protection against murine cytomegalovirus infection by passive transfer of neutralizing and non-neutralizing monoclonal antibodies.
Farrell HE; Shellam GR
J Gen Virol; 1991 Jan; 72 ( Pt 1)():149-56. PubMed ID: 1846643
[TBL] [Abstract][Full Text] [Related]
25. Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin.
Tan GS; Lee PS; Hoffman RM; Mazel-Sanchez B; Krammer F; Leon PE; Ward AB; Wilson IA; Palese P
J Virol; 2014 Dec; 88(23):13580-92. PubMed ID: 25210195
[TBL] [Abstract][Full Text] [Related]
26. A Novel
Spurgeon ME; Uberoi A; McGregor SM; Wei T; Ward-Shaw E; Lambert PF
mBio; 2019 Mar; 10(2):. PubMed ID: 30837335
[TBL] [Abstract][Full Text] [Related]
27. Comprehensive Assessment of the Antigenic Impact of Human Papillomavirus Lineage Variation on Recognition by Neutralizing Monoclonal Antibodies Raised against Lineage A Major Capsid Proteins of Vaccine-Related Genotypes.
Godi A; Boampong D; Elegunde B; Panwar K; Fleury M; Li S; Zhao Q; Xia N; Christensen ND; Beddows S
J Virol; 2020 Nov; 94(24):. PubMed ID: 32967963
[TBL] [Abstract][Full Text] [Related]
28. Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions.
Balmelli C; Roden R; Potts A; Schiller J; De Grandi P; Nardelli-Haefliger D
J Virol; 1998 Oct; 72(10):8220-9. PubMed ID: 9733865
[TBL] [Abstract][Full Text] [Related]
29. Airway Delivery of Anti-influenza Monoclonal Antibodies Results in Enhanced Antiviral Activities and Enables Broad-Coverage Combination Therapies.
Vigil A; Frias-Staheli N; Carabeo T; Wittekind M
J Virol; 2020 Oct; 94(22):. PubMed ID: 32847855
[TBL] [Abstract][Full Text] [Related]
30. Mouse Papillomavirus L1 and L2 Are Dispensable for Viral Infection and Persistence at Both Cutaneous and Mucosal Tissues.
Brendle S; Li JJ; Cladel NM; Shearer DA; Budgeon LR; Balogh KK; Atkins H; Costa-Fujishima M; Lopez P; Christensen ND; Doorbar J; Murooka TT; Hu J
Viruses; 2021 Sep; 13(9):. PubMed ID: 34578405
[TBL] [Abstract][Full Text] [Related]
31. Depo Medroxyprogesterone (DMPA) Promotes Papillomavirus Infections but Does Not Accelerate Disease Progression in the Anogenital Tract of a Mouse Model.
Hu J; Brendle SA; Li JJ; Walter V; Cladel NM; Cooper T; Shearer DA; Balogh KK; Christensen ND
Viruses; 2022 May; 14(5):. PubMed ID: 35632722
[TBL] [Abstract][Full Text] [Related]
32. Spontaneously regressing oral papillomas induce systemic antibodies that neutralize canine oral papillomavirus.
Ghim S; Newsome J; Bell J; Sundberg JP; Schlegel R; Jenson AB
Exp Mol Pathol; 2000 Jun; 68(3):147-51. PubMed ID: 10816383
[TBL] [Abstract][Full Text] [Related]
33. Induction of neutralizing antibodies to papillomaviruses by anti-idiotypic antibodies.
Christensen ND; Reed CA; Cladel NM
Virology; 1995 Jul; 210(2):292-301. PubMed ID: 7542415
[TBL] [Abstract][Full Text] [Related]
34. Induction of protective cytotoxic T cell responses in the presence of high titers of virus-neutralizing antibodies: implications for passive and active immunization.
Seiler P; Bründler MA; Zimmermann C; Weibel D; Bruns M; Hengartner H; Zinkernagel RM
J Exp Med; 1998 Feb; 187(4):649-54. PubMed ID: 9463415
[TBL] [Abstract][Full Text] [Related]
35. Use of monoclonal antibody directed against herpes simplex virus glycoproteins to protect mice against acute virus-induced neurological disease.
Dix RD; Pereira L; Baringer JR
Infect Immun; 1981 Oct; 34(1):192-9. PubMed ID: 6271681
[TBL] [Abstract][Full Text] [Related]
36. In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity.
Staats HF; Alam SM; Scearce RM; Kirwan SM; Zhang JX; Gwinn WM; Haynes BF
Infect Immun; 2007 Nov; 75(11):5443-52. PubMed ID: 17709410
[TBL] [Abstract][Full Text] [Related]
37. Oral administration of HPV-16 L2 displayed on Lactobacillus casei induces systematic and mucosal cross-neutralizing effects in Balb/c mice.
Yoon SW; Lee TY; Kim SJ; Lee IH; Sung MH; Park JS; Poo H
Vaccine; 2012 May; 30(22):3286-94. PubMed ID: 22426329
[TBL] [Abstract][Full Text] [Related]
38. Passive immune protection by herpes simplex virus-specific monoclonal antibodies and monoclonal antibody-resistant mutants altered in pathogenicity.
Kümel G; Kaerner HC; Levine M; Schröder CH; Glorioso JC
J Virol; 1985 Dec; 56(3):930-7. PubMed ID: 2415719
[TBL] [Abstract][Full Text] [Related]
39. Concatenated multitype L2 fusion proteins as candidate prophylactic pan-human papillomavirus vaccines.
Jagu S; Karanam B; Gambhira R; Chivukula SV; Chaganti RJ; Lowy DR; Schiller JT; Roden RB
J Natl Cancer Inst; 2009 Jun; 101(11):782-92. PubMed ID: 19470949
[TBL] [Abstract][Full Text] [Related]
40. Immunization with a consensus epitope from human papillomavirus L2 induces antibodies that are broadly neutralizing.
Tyler M; Tumban E; Dziduszko A; Ozbun MA; Peabody DS; Chackerian B
Vaccine; 2014 Jul; 32(34):4267-74. PubMed ID: 24962748
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
